After various reports highlighted a shortage for Moderna’s new bivalent omicron booster, it seems production issues at a Catalent plant were at the center of the problem. But Moderna expects “availability constraints” to be resolved soon. Adamis’ sole clinical-stage asset, Tempol, has failed a study in COVID-19, triggering a steep share-price decline. But CEO David Marguglio maintained that the company is “bullish” about the prospects for its two approved drugs. After increasing its stake in specialty pharmacy company Shields Health Solutions last year, Walgreens is ready to buy out the rest of the firm. Along with news of the purchase, Walgreens revealed a pair of exec moves. - Eric Sagonowsky | 